Jazz Pharmaceuticals: Cozadd proposes $1.3M sale
Three earlier sales are listed, each involving 6,000 common shares, on August 3, September 1 and October 1, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Jazz Pharmaceuticals plc (JAZZ) officer Bruce C. Cozadd reported a proposed sale of 6,000 common shares, with an aggregate market value of $1,295,040. Merrill Lynch is listed as the broker, NASDAQ as the exchange, and November 2, 2026 as the approximate sale date.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option financial
Aggregate market value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.